The efficiency of a urotensin II antagonist in an experimental lung fibrosis model

Inflammation

Volumn 35, Issue 3, 2012, Pages 1138-1143

  Onat, Ahmet Mesut ^a   Turkbeyler, Ibrahim Halil ^a   Pehlivan, Yavuz ^a   Demir, Tuncer ^a   Kaplan, Davut Sinan ^a   Taysi, Seyithan ^a   Ceribasi, Ali Osman ^b   Tutar, Ediz ^a   Kisacik, Bunyamin ^a  

^a GAZIANTEP UNIVERSITY   (Turkey)

^b FIRAT UNIVERSITY   (Turkey)

Author keywords

Endothelin 1; Lung fibrosis; Palosuran; Urotensin II antagonist

Indexed keywords

BLEOMYCIN; ENDOTHELIN 1; PALOSURAN; TRANSFORMING GROWTH FACTOR BETA1; UROTENSIN II;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; LUNG FIBROSIS; MALE; NONHUMAN; PROTEIN BLOOD LEVEL; RAT; RISK ASSESSMENT;

ANIMALS; BLEOMYCIN; ENDOTHELIN-1; LUNG; MALE; PULMONARY FIBROSIS; QUINOLINES; RANDOM ALLOCATION; RATS; RATS, WISTAR; TRANSFORMING GROWTH FACTOR BETA1; UREA; UROTENSINS;

ANIMALIA; RATTUS;

EID: 84863797923     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-011-9421-6     Document Type: Article

References (31)

1. Cook, D.N., D.M. Brass, and D.A. Schwartz. 2002. A matrix for new ideas in pulmonary fibrosis. American Journal of Respiratory Cell and Molecular Biology 27: 122-1244.
2. Ozyurt, H., S. Söǧüt, Z. Yildirim, L. Kart, M. Iraz, F. Armutçu, I. Temel, S. Ozen, A. Uzun, and O. Akyol. 2004. Inhibitory effect of caffeic acid phenethyl ester (cape) on bleomycine-induced lung fibrosis in rats. Clinica Chimica Acta 339: 65-75. (Pubitemid 37542459)
3. Daniil, Z.D., F.C. Gilchrist, A.G. Nicholson, D.M. Hansell, J. Harris, T.V. Colby, and R.M. du Bois. 1999. A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. American Journal of Respiratory and Critical Care Medicine 160: 899-905. (Pubitemid 29442028)
4. Mason, R.J., M.I. Schwarz, G.W. Hunninghake, and R.A. Musson. 1999. NHLBI Workshop Summary. Pharmacological therapy for idiopathic pulmonary fibrosis. Past, present, and future. American Journal of Respiratory and Critical Care Medicine 160: 1771-1777.
5. Park, S.H., D. Saleh, A. Giaid, and R.P. Michel. 1997. Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. American Journal of Respiratory and Critical Care Medicine 156: 600-608. (Pubitemid 27352001)
6. King Jr., T.E., J. Behr, K.K. Brown, R.M. du Bois, L. Lancaster, J.A. de Andrade, G. Stähler, I. Leconte, S. Roux, and G. Raghu. 2008. BUILD-1: A randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine 177: 75-81.
7. Coulouarn, Y., I. Lihrmann, S. Jegou, Y. Anouar, H. Tostivint, J.C. Beauvillain, J.M. Conlon, H.A. Bern, and H. Vaudry. 1998. Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. Proceedings of the National Academy of Sciences of the United States of America 95: 15803-15808. (Pubitemid 29018781)
8. Wang, H., J.L. Mehta, K. Chen, X. Zhang, and D. Li. 2004. Human urotensin II modulates collagen synthesis and the expression of MMP-1 in human endothelial cells. Journal of Cardiovascular Pharmacology 44: 577-581. (Pubitemid 39441698)
9. Tran, L., A.R. Kompa,W. Kemp, A. Phrommintikul, B.H.Wang, and H. Krum. 2010. Chronic urotensin-II infusion induces diastolic dysfunction and enhances collagen production in rats. American Journal of Physiology. Heart and Circulatory Physiology 298: 608-613.
10. Pehlivan, Y., A.M. Onat, G. Comez, and T. Babacan. 2001. Urotensin-II in systemic sclerosis: A new peptide in pathogenesis. Clinical Rheumatology 28. Epub ahead of print.
11. Pehlivan, Y., B. Gogebakan, S. Oztuzcu, M. Ozgen, G.Y. Cetin, R. Bayraktar, B. Cengiz, B. Kisacik, S.S. Koca, S. Donmez, M. Sayarlioglu, A.T. Demiryurek, and A. M. Onat. 2011. Association between Thr21Met and Ser89Asn polymorphisms of the urotensin II gene and systemic sclerosis. J Rheumatol Nov 1. (In press).
12. Sidharta, P.N., P.L. van Giersbergen, and J. Dingemanse. 2009. Pharmacokinetics and pharmacodynamics of the urotensin-II receptor antagonist palosuran in healthy male subjects. Journal of Clinical Pharmacology 49: 1168-1175.
13. Chen, L., T. Wang, X. Wang, B.B. Sun, J.Q. Li, D.S. Liu, S.F. Zhang, L. Liu, D. Xu, Y.J. Chen, and F.Q. Wen. 2009. Blockade of advanced glycation end product formation attenuates bleomycin-induced pulmonary fibrosis in rats. Respiratory Research 10: 55.
14. Clozel, M., P. Hess, C. Qiu, S.S. Ding, and M. Rey. 2006. The urotensin-II receptor antagonist palosuran improves pancreatic and renal function in diabetic rats. Journal of Pharmacology and Experimental Therapeutics 316: 1115-1121. (Pubitemid 43345285)
15. Ashcroft, T., J.M. Simpson, and V. Timbrell. 1988. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. Journal of Clinical Pathology 41: 467-470. (Pubitemid 18098428)
16. Society, A.T. 2009. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). American Journal of Respiratory and Critical Care Medicine 161: 646-664.
17. Broekelmann, T.J., A.H. Limper, T.V. Colby, and J.A. McDonald. 1991. Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proceedings of the National Academy of Sciences of the United States of America 88: 6642-6646. (Pubitemid 21915005)
18. Atamas, S.P., and B. White. 2003. Cytokine regulation of pulmonary fibrosis in scleroderma. Cytokine & Growth Factor Reviews 14: 537-550. (Pubitemid 37296026)
19. Whyte, M., R. Hubbard, R. Meliconi, M. Whidborne, V. Eaton, C. Bingle, J. Timms, G. Duff, A. Facchini, A. Pacilli, M. Fabbri, I. Hall, J. Britton, I. Johnston, and F. Di Giovine. 2000. Increased risk of fibrosing alveolitis associated with interleukin-1 receptor antagonist and tumor necrosis factor-alpha gene polymorphisms. American Journal of Respiratory and Critical Care Medicine 162: 755-758. (Pubitemid 30647230)
20. Jiang, D., J. Liang, J. Hodge, B. Lu, Z. Zhu, S. Yu, J. Fan, Y. Gao, Z. Yin, R. Homer, C. Gerard, and P.W. Noble. 2004. Regulation of pulmonary fibrosis by chemokine receptor CXCR3. The Journal of Clinical Investigation 114: 291-299. (Pubitemid 39071634)
21. Raghu, G., K.K. Brown, W.Z. Bradford, K. Starko, P.W. Noble, D.A. Schwartz, and T.E. King Jr. 2004. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. The New England Journal of Medicine 350: 125-133. (Pubitemid 38056223)
22. Meadors, M., J. Floyd, and M.C. Perry. 2006. Pulmonary toxicity of chemotherapy. Seminars in Oncology 33: 98-105. (Pubitemid 43214490)
23. Sleijfer, S. 2001. Bleomycin-induced pneumonitis. Chest 120: 617-624. (Pubitemid 32881285)
24. Chandler, D.B., J.C. Barton, D.D. Briggs, T.W. Butler, J.I. Kennedy, W.E. Grizzle, and J.D. Fulmer. 1988. Effect of iron deficiency on bleomycin-induced lung fibrosis in the hamster. American Review of Respiratory Disease 137: 85-89. (Pubitemid 18032830)
25. Douglas, S.A., A.C. Sulpizio, V. Piercy, H.M. Sarau, R.S. Ames, N.V. Aiyar, E.H. Ohlstein, and R.N. Willette. 2000. Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. British Journal of Pharmacology 131: 1262-1274.
26. Cosenzi, A. 2008. Non peptidic urotensin II antagonists: Perspectives for a new class of drugs. Cardiovascular & Hematological Agents in Medicinal Chemistry 6: 80-91. (Pubitemid 351935015)
27. Bousette, N., J. Pottinger, W. Ramli, E.H. Ohlstein, D. Dhanak, S.A. Douglas, and A. Giaid. 2006. Urotensin-II receptor blockade with SB-611812 attenuates cardiac remodeling in experimental ischemic heart disease. Peptides 27: 2919-2926. (Pubitemid 44584417)
28. Simpson, C.M., J.J. Smolich, L.S. Shekerdemian, and D.J. Penny. 2010. Urotensin-II contributes to pulmonary vasoconstriction in a perinatal model of persistent pulmonary hypertension of the newborn secondary to meconium aspiration syndrome. Pediatric Research 67: 150-157.
29. Trebicka, J., L. Leifeld, M. Hennenberg, E. Biecker, A. Eckhardt, N. Fischer, A.S. Pröbsting, C. Clemens, F. Lammert, T. Sauerbruch, and J. Heller. 2008. Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats. Hepatology 47: 1264-1276. (Pubitemid 351547913)
30. Tian, L., C. Li, J. Qi, P. Fu, X. Yu, X. Li, and L. Cai. 2008. Diabetes-induced upregulation of UII and plays an important role in TGF-beta1- mediated renal fibrosis and dysfunction. American Journal of Physiology. Endocrinology and Metabolism 295: 1234-1242.
31. Sidharta, P.N., F.D. Wagner, H. Bohnemeier, A. Jungnik, A. Halabi, S. Krähenbühl, H. Chadha-Boreham, and J. Dingemanse. 2006. Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in macroalbuminuric, diabetic patients. Clinical Pharmacology and Therapeutics 80: 246-256. (Pubitemid 44313907)